BioPharma Credit PLC Transaction in Own Shares (3574A)

TIDMBPCR

RNS Number : 3574A

BioPharma Credit PLC

19 January 2024

BioPharma Credit plc

(the "Company")

TRANSACTION IN OWN SHARES

BioPharma Credit PLC (the "Company") announces that today it has purchased the following number of its ordinary shares of US$0.01 each on the London Stock Exchange through J.P. Morgan Securities plc into treasury.

Ordinary Shares: BPCR LN

Date of purchase: 19 January 2024

Number of ordinary shares purchased: 747,469

Lowest price per share: $0.9400

Highest price per share: $0.9420

Trading venue: London Stock Exchange

Ordinary Shares: BPCR LN

Date of purchase: 19 January 2024

Number of ordinary shares purchased: 500,000

Lowest price per share: $0.9400

Highest price per share: $0.9400

Trading venue: JPSI

Aggregate volume per date per trading venue: 1,247,469

Weighted average price per day per trading venue: $0.9408

Following the above transaction, the Company holds 92,848,973 of its ordinary shares in treasury and has 1,281,083,094 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,281,083,094. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

[phone]

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

[phone]

[e-mail]

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSDKLFFZFLFBBF

(END) Dow Jones Newswires

January 19, 2024 13:15 ET (18:15 GMT)